Please assess the completion status of the following clinical trial:

Trial Title: Study Examining PrEP-001 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Young healthy adults as determined by medical history, physical examination, serology (HIV and Hepatitis B and C) and clinical laboratory tests.~* Female subjects were required to provide of a history of reliable contraceptive practice.~Exclusion criteria:~* Subjects who have a significant history of any tobacco use at any time.~* Any history or evidence of any clinically significant cardiovascular, dermatological gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic, urological, neurological, psychiatric, renal disease.~* Abnormal ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort A: Sentinel Group (Type: OTHER): Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
- Cohort B: PrEP-001 (Type: EXPERIMENTAL): PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
- Cohort B: Placebo (Type: EXPERIMENTAL): Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).